Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Phase 2 Completed 25 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.

Timeline

Start: 2006-01
Primary completion: 2006-10
Completion: —

Publications

Results Zhou Q, Wong CH, Lau CP, Hui CW, Lui VW, Chan SL, Yeo W. Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:103830. doi: 10.1155/2013/103830. Epub 2013 Feb 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Patupilone	Small molecule	10 mg/m2	Intravenous

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Summary

Timeline

Publications

Drugs

Indications